Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In SelectQuote (SLQT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in SelectQuote between September 9, 2020 and May 1, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happe ...

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its competitive position and financial guidance during the Class Period from May 7, 2025, to August 5, 2025 [2][3]. Allegation Details - The lawsuit claims that LifeMD's defendants overstated the company's competitive position and were reckless in raising the 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [3]. - It is alleged that the defendants' statements about LifeMD's business operations and prospects were materially false and misleading, leading to investor damages when the true information became public [3]. Next Steps - Investors who purchased LifeMD shares during the Class Period and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [8] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [8] - A subsequent Complete Response Letter from the FDA on June 30, 2025, citing the same deficiencies, caused the stock to drop nearly 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [4][5] - The firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4]

Core Viewpoint - A class action lawsuit has been filed against Lineage, Inc. for alleged material misrepresentations in its IPO registration statement, which misled investors about the company's business and financial health [7]. Allegation Details - The lawsuit claims that the Registration Statement contained false information regarding Lineage's business performance and industry trends at the time of the IPO, particularly regarding the impact of the COVID-19 pandemic on cold storage demand [7]. - It is alleged that instead of experiencing growth, Lineage was facing a downturn as customers reduced inventory levels and the company struggled with occupancy rates and pricing power due to unsustainable price increases [7]. Stock Performance - Since the IPO, Lineage's stock price has dropped to approximately $40 per share, which is about half of the IPO price [7].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Encompass Health Corporation for possible violations of federal securities laws and unlawful business practices [1][2] Investigation Details - The investigation is prompted by allegations from a New York Times article published on July 15, 2025, which stated that Encompass's for-profit hospitals perform below average on key safety measures [6] - The article highlighted that Encompass owns 34 facilities rated by Medicare as having statistically significantly worse rates of potentially preventable readmissions, indicating serious operational issues [6] Stock Impact - Following the publication of the article, Encompass's stock price dropped by $12.39, or 10.4%, closing at $107.28 per share on July 15, 2025, resulting in financial losses for investors [6]

Core Viewpoint - A class action lawsuit has been filed against CTO Realty Growth, Inc. for alleged misrepresentation of its financial health and sustainability of dividends during the class period from February 18, 2021, to June 24, 2025 [2][8]. Allegation Details - The lawsuit claims that CTO failed to disclose that its dividends were less sustainable than represented, used deceptive practices to inflate Adjusted Funds from Operations (AFFO), and overstated the profitability of its Ashford Lane property [8]. - A report by Wolfpack Research accused CTO of not generating sufficient cash to cover its recurring capital expenditures and dividends since converting to a REIT in 2021, relying on share dilution to cover a $38 million dividend shortfall from 2021 to 2024, and employing a misleading definition of AFFO [8]. - The report highlighted that CTO had only $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million, along with additional planned capital expenditures of approximately $12 million [8]. Next Steps - Investors who purchased CTO shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [4].

Core Viewpoint - A class action lawsuit has been filed against KinderCare Learning Companies, Inc. for allegedly misleading investors regarding the quality of care provided at its facilities and undisclosed risks associated with its IPO [1][6]. Allegation Details - The lawsuit claims that the registration statement for KinderCare's IPO was false and/or misleading, failing to disclose incidents of child abuse, neglect, and harm at its facilities [6]. - It is alleged that KinderCare did not provide the "highest quality care possible" and failed to meet basic standards in the child care industry, exposing the company to material risks including lawsuits and reputational damage [6]. Stock Performance - Following the IPO, KinderCare's stock price has fallen to lows near $9 per share, indicating a significant decline in investor confidence [6].

Core Viewpoint - A class action lawsuit has been filed against Lineage, Inc. for alleged material misrepresentations in its IPO registration statement, which misled investors about the company's business and financial health [8]. Allegation Details - The lawsuit claims that the Registration Statement contained false information regarding Lineage's business performance and industry trends at the time of the IPO, particularly regarding the impact of the COVID-19 pandemic on cold storage demand [8]. - It is alleged that instead of experiencing growth, Lineage was facing a downturn as customers reduced inventory levels and the company struggled with occupancy rates and pricing power due to unsustainable price increases [8]. Stock Performance - Since the IPO, Lineage's stock price has dropped to approximately $40 per share, which is about half of the IPO price [8].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers all individuals and entities that purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [8] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [8] - On June 30, 2025, the FDA issued a Complete Response Letter for the NDA, resulting in a further stock price decline of almost 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4] - The law firm represents both individual and institutional investors in complex litigation across various courts [5]

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its treatment ALTO-100 for Major Depressive Disorder (MDD) [7]. Allegation Details - The lawsuit claims that the Offering Documents for Alto's IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [7]. - Specifically, it is alleged that ALTO-100 was less effective in treating MDD than the company had indicated, leading to overstated clinical, regulatory, and commercial prospects [7]. Stock Performance Impact - Following the announcement of the Phase 2b trial results on October 22, 2024, which indicated that ALTO-100 did not meet its primary endpoint, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [7]. Next Steps for Investors - Investors who purchased Alto securities between February 2, 2024, and October 22, 2024, are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is September 19, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina and specializes in commercial and securities litigation [5].